MedTrace Logo

Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder

NCT02811133 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2023-10-06

No results posted yet for this study

Summary

This is an open trial that seeks to determine the safety and tolerability of using inositol for children and adolescents with bipolar disorder and comorbid anxiety disorders with an exploration of efficacy and dose-response.

Conditions

Interventions

DRUG

Inositol

Subjects will receive inositol

Sponsors & Collaborators

  • The Fine Foundation

    collaborator UNKNOWN

  • Jarrow Formulas Inc

    collaborator INDUSTRY

  • Ronald M. Glick, MD

    lead OTHER

Principal Investigators

  • Ronald Glick, MD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2023-10-04
Completion
2023-10-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02811133 on ClinicalTrials.gov